Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on January 31, 2006
The European Commission has granted an orphan drug designation to an investigational anticancer drug, 1D09C3, developed for the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia.
1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the surface of cells and selectively kills activated, proliferating tumor cells, which include B-cell and T-cell lymphomas.
1D09C3 is the first internal research program to advance into human trials by GPC Biotech, a Germany-based firm focusing on oncology. Read the full press release from GPC Biotech.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/14752
Mr Wong
Vote for Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status:
|
Rating: 8.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |








